# Phoenix Molecular Designs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phoenix-molecular-designs

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.phoenixmd.ca
- Total disclosed funding: $12M
- Latest round: Series A (Sep 1, 2020)
- Investors on record: 4

## About

Phoenix Molecular Designs Ltd. specializes in developing personalized cancer therapeutics, focusing on RSK inhibition to enhance treatment efficacy for breast cancer patients.Founded in 2012 and headquartered in Vancouver, Canada, Phoenix Molecular Designs Ltd. develops innovative cancer therapies. The company executed its most recent funding round in September 2020, raising USD 0.25 mn in Series A funding from Wisdom. Sandra Dunn serves as both founder and CEO, overseeing the company’s strategic direction and operations.Phoenix Molecular Designs specializes in personalized cancer therapeutics with a strong emphasis on RSK (p90 ribosomal S6 kinase) inhibition. Their lead product, PMD-026, targets RSK2, a key player in breast cancer development and treatment resistance. The company is also developing a companion diagnostic to identify patients who will benefit from RSK-targeted therapies, ultimately improving patient outcomes. Their products primarily serve breast cancer patients and oncology healthcare providers, operating in regions with advanced healthcare systems, especially North America and parts of Europe.The revenue generation model for Phoenix Molecular Designs focuses on the commercialization of their patented cancer therapeutics and diagnostic tools, notably PMD-026. The company pursues direct-to-consumer sales and partnerships with healthcare providers and pharmaceutical firms to broaden distribution. Revenue arises from product sales and licensing agreements, which may involve upfront payments, milestone payments upon achieving development goals, and royalties on future sales. Their patented offerings suggest a premium pricing strategy based on the advanced nature of their products and significant clinical needs in oncology.In September 2020, Phoenix Molecular Designs raised USD 0.25 mn in Series A funding to support its growth initiatives. The company plans to expand its product line by launching new therapeutics that enhance cancer treatment efficacy, with specific release dates yet to be determined. Additionally, Phoenix Molecular Designs is targeting expansion into new markets within North America and Europe, aiming to capture the increasing demand for innovative oncology treatment options as it advances its research and development efforts.

## Funding rounds

- Series A, Sep 1, 2020, $0.3M — Wisdom
- Seed, Nov 20, 2019, $9.3M — Pallasite Ventures, World Changing Ventures Syndicate
- Seed, Sep 18, 2018, $2.7M — Pallasite Ventures
- Seed, Jun 1, 2012 — 51 Ventures

## Investors

- 51 Ventures (https://capitalatlas.ai/funds/51-ventures) — Seed
- Pallasite Ventures (https://capitalatlas.ai/funds/pallasite-ventures) — Seed
- World Changing Ventures Syndicate — Seed
- Wisdom (https://capitalatlas.ai/funds/wisdom) — Series A